ClostraBio, a biotech startup originating from the University of Chicago, has secured nearly $4 million in new financing. This investment aims to advance the company’s novel probiotic designed to restore compromised intestinal function.
Founded in 2016, ClostraBio has now raised over $10 million in total funding. The company’s research focuses on developing therapies to alleviate the effects of food allergies and conditions like ulcerative colitis
Keep Reading
Add A Comment